Modulakgotla Sebe
Publications by Year
Research Areas
Tuberculosis Research and Epidemiology, HIV Research and Treatment, HIV/AIDS drug development and treatment, Pneumonia and Respiratory Infections, Mycobacterium research and diagnosis
Most-Cited Works
- → Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults(2021)227 cited
- → Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial(2019)146 cited
- → Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial(2018)96 cited
- → Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial(2020)65 cited
- → A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB(2021)62 cited
- → Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk(2022)49 cited
- → Annual Tuberculosis Preventive Therapy for Persons With HIV Infection(2021)38 cited
- → Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein(2020)35 cited
- → Lung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/Tuberculosis(2019)22 cited
- → Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial(2025)20 cited